Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Doubtful use of placebo following placebo in recent controlled trials of lasmiditan and ubrogepant for the treatment of migraine attacks

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Headache provocation by nitric oxide in men who have never experienced a headache

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Prevalence of neck pain in migraine: A systematic review and meta-analysis

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Polygenic risk provides biological validity for the ICHD-3 criteria among Finnish migraine families

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Smooth muscle ATP-sensitive potassium channels mediate migraine-relevant hypersensitivity in mouse models

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Erenumab prevents the occurrence of migraine attacks and not just migraine days: Post-hoc analyses of a phase III study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Can tendon reflexes be elicited by both stretch and vibration in man?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Onset of action in placebo-controlled migraine attacks trials: A literature review and recommendation

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

Vis graf over relationer

PURPOSE: In four large controlled trials with lasmiditan and ubrogepant placebo was administered in the first step to demonstrate an effect on migraine attack. In the same trials the investigators also asked the question: is a second dose of the drug effective in non-responders to the first dose? In this phase patients who received placebo in the first phase of the trial again after 2 hours received another dose of placebo.

CONCLUSION: To be ethical, clinical research requires balancing rigorous science with the protection of human subjects; and it is, in our view, questionable whether placebo was used with "scientific rigor" in the second step of these trials, and this design is not recommended.

OriginalsprogEngelsk
TidsskriftCephalalgia : an international journal of headache
Vol/bind42
Udgave nummer1
Sider (fra-til)82-85
Antal sider4
ISSN0333-1024
DOI
StatusUdgivet - jan. 2022

ID: 68917484